Virology. Delineating Ebola entry.
Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, Saskatoon, SK Canada.
Darryl
D
Falzarano
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Hamilton, MT, USA. feldmannh@niaid.nih.gov.
Heinz
H
Feldmann
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000502:physiology*; D029043:Ebolavirus / Q000502:physiology*; D005260:Female; D019142:Hemorrhagic Fever, Ebola / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D053586:Virus Internalization / Q000187:drug effects*; D000097903:Two-Pore Channels
D000998:Antiviral Agents; D002121:Calcium Channel Blockers; D015220:Calcium Channels; C407357:TPCN1 protein, human; D000097903:Two-Pore Channels; C530224:TPCN2 protein, human